Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Infants
Condition: Prevention of Meningococcal DiseaseInterventions: Biological: MenACWY Ad- (MenACWY-CRM, non adjuvanted formulation); Biological: MenACWY Ad+ (MenACWY-CRM, adjuvanted formulation); Biological: MenACWY PS (MenACWY-CRM, polysaccharide vaccine); Biological: HBV (Hepatitis B vaccine); Biological: Prevnar (pneumococcal polysaccharide serotypes 4, 9V, 14, 18C, 19F, 23F & 6B conjugated to the CRM197); Biological: MMR (Measles, Mumps and Rubella vaccine); Biological: DTaPHibIPV (Diphtheria, Tetanus, acellular Pertussis, H. Influenzae type b, Inactivated Poliovaccine); Biological: Menjugate (Men C conjugated vaccine)Sponsors: Novartis; Novartis VaccinesCompleted - verified June 2014
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Diphtheria | Haemophilus Influenzae (Hib) | Influenza Vaccine | Measles | Measles Vaccine | Men | Meningitis | Meningitis Vaccine | Mumps | Mumps Vaccine | Pneomococcal Vaccine | Research | Rubella | Rubella Vaccine | Study | Tetanus | Tetanus Diptheria Pertussis Vaccine Tdap,Dtap,Dpt | Tetanus Vaccine | Vaccines | Whooping Cough (Pertussis) Vaccine